An assessment of short-acting β2-agonist (SABA) use and subsequent greenhouse gas (GHG) emissions in five European countries and the consequence of their potential overuse for asthma in the UK

Study found SABA represents majority of inhaler use and of GHG emissions in U.K. and its neighbours, however, U.K. SABA use and GHG emissions per capita are ~treble those of other countries, and 284,683 out of 574,913 asthma patients in UK study were potentially overusing SABA.

Source:

Thorax